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ABSTRAK 
 
Kit Ligan (KL), salah satu faktor pertumbuhan pertama dalam folikel ovarium, memainkan peran kunci dalam oogenesis mamalia 
dan folliculogenesis. KL protein dan ekspresi mRNA terdeteksi dalam sel granulosa dari folikel pada semua tahap perkembangan. 
Cisplatin adalah salah satu senyawa platinium generasi pertama dan umumnya digunakan untuk pengobatan ovarium, testis 
payudara, dan kanker kandung kemih.Tujuan dari penelitian ini adalah untuk membuktikan ekspresi yang lebih rendah dari ligan kit 
dan jumlah folikel, dan hubungan antara ekspresi ligan kit dan jumlah folikel, pada tikus (Rattus novergicus) strain wistar dengan 
cisplatin. Penelitian ini dilakukan di Laboratorium Hewan Coba dan Patologi Veteriner, Fakultas Kedokteran Hewan, Universitas 
Airlangga, Surabaya, Mei-Juli 2011. Penelitian ini dilakukan oleh randomized post test only control group design. Sampel penelitian 
ini adalah tikus (Rattus novergicus) galur wistar yang sesuai dengan kriteria inklusi. Pada periode diestrus, kelompok kontrol 
disuntik oleh IP NaCl 0,9%, dan kelompok cisplatin disuntikkan dengan cisplatin IP 5 mg/kg w. Tikus dibantai pada hari ke-7 
periode estrus pada kelompok kontrol, dan pada periode diestrus pada kelompok cisplatin. Ooforektomi dilakukan, dilanjutkan 
dengan pewarnaan immuno-histokimia dan hematoxylin eosin untuk pemeriksaan ekspresi ligan kit dan jumlah folikel. Tidak 
didapatkan hubungan antara ekspresi ligan kit dan jumlah folikel primordial, primer, sekunder, dan tersier (p = 0,945, p = 0,180, p 
= 0.590, p = 0.753) pada tikus dengan cisplatin. Sebagai kesimpulan, pada tikus dengan cisplatin, ekspresi ligan kit, jumlah folikel 
primordial, primer,  sekunder, dan tersier rendah. (MOG 2011;19:102-108) 
 
Kata kunci: ekspresi ligan kit, jumlah folikel, cisplatin, folikulogenesis, tikus 
 
 
ABSTRACT 
 
Kit Ligand (KL), one of the first growth factors in ovarian follicle, plays a key role in mammalian oogenesis and folliculogenesis. KL 
protein and mRNA expression is detected in the granulosa cells of follicles at all stages of development. Cisplatin is one of the first 
generation platinium compounds and is commonly used for treatment of ovarian, breast, testicular, and bladder cancers.The 
objective of this study was to prove the lower expression of kit ligand and amount of follicles, and the association between the 
expression of kit ligand and the amount of follicles, on rat (Rattus novergicus) strain wistar with cisplatin. This study was conducted 
at Laboratory of Experimental Animal and Veterinary Patology, Faculty of Veterinary, Airlangga University, Surabaya, May-July 
2011. The research was performed by randomized post test only control group design. The research samples were Rat (Rattus 
novergicus) strain wistar which was admitted into inclusion criteria. At the diestrus period, the control group was injected by NaCl 
0.9% IP, and the cisplatin group was injected by cisplatin 5 mg/kg w IP. The rat were slaughtered at the 7th day of estrus period on 
the control group, and at the diestrus period on the cisplatin group. Oophorectomy was performed, continued with immuno- 
histochemistry staining and hematoxylin eosin for examination on expression of kit ligand and amount of follicles. We achieved no 
association among the expression of kit ligand and the amounts of primordial, primary, secondary, and tertiary follicles (p=0.945, 
p=0.180, p=0.590, p=0.753) on the rat with cisplatin. In conclusion, In rat with cisplatin, the expresssion of kit ligand, the amount of 
primordial, primary, secondary, and tertiary follicles are low.  (MOG 2011;19:102-108) 
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INTRODUCTION 
 
Over the past three decades, there has been a remarkable 
improvement in the survival rates due to progress in 
cancer treatment.1 In the past, the primary goal of cancer 
therapy—survival—tended to overshadow survivorship 
considerations. However, with recent advances in 
oncology, survival rates are increasing, and therefore, 
issues affecting long-term cancer survivors become 
more important and more widely recognized.2 As a 
consequence of the increase in the number of patients 
surviving cancer, greater attention has been focused on 
the delayed effects of cancer treatments on the quality 
of future life of the survivor.1 An unfortunate and 
devastating consequence of chemotherapy is ovarian 
damage; leading to diminished fertility potential and 
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lower post treatment birth rates in female cancer 
survivors. Specifically, malignancy on women 1179 and 
1261 people. While data on Pharmacy Installation of dr 
Soetomo State Hospital showed that the amount of 
female patients with malignancy and receive cisplatin 
chemotherapy at 2009 and 2010 consecutively are 300 
and 457 patients. 
 
Young patients treated with chemotherapy or 
radiotherapy may suffer from gonadal damage and 
permanent ovarian failure. Most studies on the 
deleterious effects of chemotherapy on human ovaries 
have focused on indirect parameters of ovarian failure, 
such as menstrual history, hormone levels and 
subsequent pregnancies. Ovarian failure after treatment 
was found to be related to the age of the patient, and 
treatment protocols. Histological studies of human 
ovaries demonstrated that the end result of chemo-
therapy was ovarian atrophy and anticancer drugs 
diminish the primordial follicle pool, cause ovarian 
atrophy, and harm the ovarian blood vasculature.3 The 
number of childhood cancer survivors in the United 
States was 270,000 in 2003, and the prevalence of 
cancer survivors among young adults (15 to 45 y of age) 
in the United States will be 1 in 250 people in 2010.4 
Cancer affects over 11,000 global loss of primordial 
follicles.6 The study uses experimental animal such as 
rat (Rattus novergicus) strain wistar for replacing 
human for more invasive research which has been 
inhibited by ethic on the execution. Folliculogenesis is 
the process by which the female germ cell develops 
within the somatic cells of the ovary and matures 
patients per year in the UK in the 15–40 into a 
fertilizable egg.7 
 
The follicular years age group, comprising 4% of 
patients with cancer.5 Data of year 2009 and 2010 in 
Department of Anatomic Pathology Faculty of Medicine 
Airlangga University/dr Soetomo State Hospital 
Surabaya shows that amount of women with age 15-35 
years old who suffered from malignancy consecutively 
are 178 and 169, from total development starts from the 
smallest primordial follicles recruited into the growth 
pool through primary, preantral, and antral stages to the 
largest Graafian or preovulatory follicles (POFs) that 
ovulate in response to the luteinizing hormone (LH) 
surge. After ovulation, the remaining granulosa cells 
and theca cells within the POFs differentiate into luteal 
cells to form the corpus luteum (CL).8 
 
Folliculogenesis can be divided into two phases. The 
first phase, termed the preantral or gonadotropin-
independent phase, is characterized by the growth and 
differentiation of the oocyte. The second, termed the 
antral or gonadotropin-dependent phase, is characterized 
by the tremendous increase of the size of the follicle 
itself (up to approximately 25-30 mm). The preantral 
phase is controlled mainly by locally produced growth 
factors through autocrine/paracrine mechanisms. The 
second phase is regulated by FSH and LH as well as by 
growth factors. There is great interest in the growth 
factors because they can stimulate cell proliferation and 
modulate gonadotropin action.8 
 
During the last decade, the role of growth factors in 
ovarian folliculogenesis has been extensively studied in 
several species, including rodents, domestic animals, 
and humans. In particular, Kit Ligand (KL), which was 
one of the first growth factors identified in the ovarian 
follicle, plays a key role in mammalian oogenesis and 
folliculogenesis. Since its identification in 1990, in vivo 
and in vitro studies have shown that the functions of this 
system in the ovary include the establishment of 
primordial germ cells (PGCs), activation of primordial 
follicles, oocyte survival and growth, proliferation of 
granulosa cells, recruitment of theca cells, and 
maintenance of meiotic competence.9 
 
In post-natal mouse ovaries, KL protein and mRNA 
expression is detected in the granulosa cells of follicles 
at all stages of development, though its expression is 
very low in primordial and primary follicles, and in the 
cumulus cells of antral follicles. While only limited 
primordial follicle granulosa cell staining is detected in 
mice, more than 90% of primordial follicles in sheep 
consist of at least one granulosa cell expressing KL 
protein. Moreover, KL protein is detected in the oocytes 
of resting and growing murine follicles, presumably as a 
consequence of receptor-mediated endocytosis.10 
 
Cisplatin is one of the first generation platinium 
compounds and is commonly used for treatment of 
ovarian, breast, testicular, and bladder cancers. Cisplatin 
exerts its cytotoxic effects by covalently binding to 
DNA with preferential binding to N-7 positions of 
guanine and adenine, producing intrastrand and 
interstrand cross-links. Cisplatin also binds to nuclear 
and cytoplasmic proteins, which may cause toxic 
effect.11 
 
 
MATERIAL AND METHODS 
 
The study was laboratory experimental research on 
experimental rats with randomized post test only control 
group design. The research subjects were divided 
randomly into two groups, one group as the control and 
the other one received cisplatin and the variable 
measurement were performed at the end of the research. 
The research was performed at May-July 2011, in 
Experimental Animal Laboratory and Veterinary 
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Pathology Laboratory Faculty of Vetrinary Medicine 
Airlangga University Surabaya. 
 
The research sample was rat (Rattus novergicus) strain 
female wistar, three months old, weigh 150-200 grams. 
The research samples were divided into two groups, the 
P0 group receives NaCl 0.9% injection intraperitoneal 
(IP) at diestrus period and the PI group receives 
cisplatin injection 5 mg/kgw IP at diestrus period, then 
on both groups were performed ovarian surgery by the 
7th day at estrus period. The amount of samples were 
16/groups based on Federer-Federer samples, so the 
whole total of sample is 32 rats. 
 
Inclusion criterias included female rat (Rattus 
novevrrgicus) strain wistar, three months old, weigh 
150-200 grams, virgin (no history of copulation), 
healthy, signed with tender feather, shiny eyes, not 
lame, no presence of scar. Exclusion criterias included 
history of being used as other research’s experimental 
animal, sick rat drop-out criteria of experiment, dead, or 
trapped by the cage after getting treatment. 
 
Independent variable was cisplatin. Dependent variables 
were primordial follicles, primary follicles, secondary 
folllicles, tertiary follicles, and expression of kit ligand. 
While control variables were type of experimental 
animals, sex of experimental animals, age of ex-
perimental animals, physical health, maintenance and 
care of experimental animals, and the making of 
histological preparation. 
 
All experimental animals used were taken from Utomo 
Farm of Batu City. The experimental animal that we 
used were female rat (Rattus novergicus) strain wistar 
aged about three months with weigh 150-200 grams, 
selected based on inclusion criteria and not include to 
exclusion criteria. Adaptation of experimental animals 
lasted for a week before in a clean, enough of air and 
light cage, with enough food and drink and homogen. 
Those rats were divided into two groups which each 
consist of 16 rats randomly. At diestrus period, the P0 
group received treatment by NaCl 0.9% injection IP, the 
P1 received treatment by cisplatin injection 5 ml/kgw 
IP. 
 
On the both groups of rat at estrus period at the seventh 
day, performed surgery and oophorectomy. Then the 
ovaries were given codes. The ovaries were sent to 
Laboratory of Veterinary Pathology for creating 
histological preparation and performed hematoxilin-
eosin staining to count amounts of primordial, primary, 
secondary, and tertiary follicles seen microscopically. 
Immunohistochemistry staining were performed to see 
the expression of kit ligand. After the preparation had 
been read, they were performed code opening, and the 
data of the study were recorded in forms of data 
recording. Data analysis used software self propelled 
semi submersible (SPSS). 
 
We performed examination on the expression of KL and 
the amount of follicles on the control and the cisplatin 
groups. The rat’s weight was tested by Levine’s Test to 
see the sample homogenity. Data normality test used 
Kolmogorov Smirnov test for testing the data normality 
of the expression of kit ligand and the amount of 
follicles. The data of the study distributed normally, so 
the comparation test were performed with T- paired test. 
Correlation test was performed by Pearson Test. We 
used significancy level in the study about 0.05. Ethical 
properness was achieved from Animal Care and Use 
Committee Faculty of Veterinary Medicine Airlangga 
University Surabaya. 
 
 
RESULTS AND DISCUSSION 
 
The weigh of rat that we used in the cisplatin and the 
control groups, p = 0.0001. Research ranged around 
150-175 grams. On the cisplatin group, we achieved the 
mean of the pre-treatment weigh 159.06 + 7.12 grams 
and the mean of the post-treatment weigh 165.63 ± 7.72 
grams. While on the control group we achieved the 
mean of early weigh was 161.56 ± 7.89 grams and the 
mean of end weigh was 168.75 ± 6.95 grams. Then we 
performed homogenity test on data of the early and the 
end weigh of the both groups by Levine’s Test. The 
result was, the early weigh (p = 0.396) and the end 
weigh (p = 0.69) were homogenous. The study intended 
to explain the follliculogenesis impairment on rats 
which got cisplatin. The analyzed variables were 
expression of kit ligand and amount of folllicles.  
 
Then we performed test of data normality on the 
research variables. The test of normality data was 
performed by Kolmogorov-Smirnov test with 
significancy level 0.05.The results of normality test 
Kolmogorov-Smirnov showed that the amount of the 
expression of kit ligand (p =0.922), the amount of 
primordial (p =0.381), primary (p = 0.386), secondary 
(p = 0.1) and tertiary follicles (p = 0.06) distributes 
normal with p > 0.05. By the normal distribution result, 
the comparation test was performed by using T-paired 
test. 
 
On the study, we achieved the ampunt of the expression 
of kit ligand on cisplatin group was 12.19 + 2.95 and on 
the control group was 20.17 + 2.10. After we performed 
comparation by T-paired test, we got significant 
difference between the cisplatin and the control groups, 
p = 0.0001. We counted the amount of follicles and 
found that on cisplatin group, the amount of primordial 
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follicles was 4.31 +1.19, the primary follicles was 3.81 
+ 1.22, the secondary follicles was 2.88 + 0.96 and the 
tertiary follicles was 1.38 + 0.50. While on the control 
group, the amount of primordial follicles was 6.13 + 
1.2, the primary follicles was 4.94 + 1.61, the secondary 
follicles was 4.25 + 0.78 and the tertiary follicles was 
3.69 + 1.19. Then we performed comparation test by T-
paired test, we achieved significant difference between 
cisplatin and control groups on all follicles, with 
significancies of primordial follicles p = 0.0001, 
primary follicles p = 0.034, secondary folicles p = 
0.0001, and tertiary follicles p = 0.0001. 
 
To find out the association between the expression of kit 
ligand and the amount of follicles on cisplatin group, we 
performed correlation test. The correlation on this study 
used the Pearson correlation test because the test of data 
normality resulted to normal distributed data. 
Correlation test on cisplatin group resulted that, the 
association between expression of kit ligand and 
primordial follicles was p = 0.945, expression of kit 
ligand and primary follicles was p = 0.18, expression of 
kit ligand and secondary follicles was p = 0.59, 
expression of kit ligand and tertiary follicles was p = 
0.753. So, the result of correlation test was not 
significant because p > 0.05. 
 
 
DISCUSSION 
 
The adult mammalian ovary is a complex organ 
composed of various cell types including oocytes, 
granulosa, theca, stroma and surface epithelial cells. 
These cell types are further divided into various 
subtypes. For example, the granulosa cells can be 
further differentiated into mural, cumulus, corona 
radiata or luteal cells, while theca cells develop into 
internal, external and luteal cells. The coordinated 
control of proliferation, differentiation and apoptosis of 
these cell types forms the underlying basis for menstrual 
or estrous cycles in mammals. The mechanism by which 
each cell type obtains its state of proliferation and/or 
differentiation is the subject of intense study and it has 
been shown that, as well as endocrine compounds, 
locally produced factors can regulate or modulate these 
developmental processes.12 
 
Kit ligand (KL), encoded by the Steel (Sl) gene, is a 
locally produced factor that is thought to have many 
roles in ovarian function. KL mRNA expression in 
follicles is, however, localized to granulosa cells in all 
species studied so far and can be expressed as either a 
membrane-bound or a soluble protein, depending on 
how the mRNA is spliced. Both transcripts, when 
translated, yield membrane-associated products, but 
KL-1 is efficiently cleaved and released as a soluble 
product due to a proteolytic cleavage site encoded by an 
84- base pair exon. The other form, KL-2, lacks this 
cleavage site and therefore remains membrane-bound. 
The membrane-bound KL is the more potent of the 
twoformswith regard to its ability to induce the 
proliferation of primordial germ cells. Both membrane-
bound and soluble forms of KL are present in the mouse 
ovary.12 
 
The process by which a follicles matures from the 
primordial to the preovulatory stage, with many steps 
in- between is referred to as folliculogenesis. This 
development involves two major processes, i.e., 
recruitment of the follicle into the growing pool and the 
proliferation and differentiation of the granulosa and 
theca cells. The first of these processes is regulated by 
paracrine and autocrine signals produced in the ovary 
itself; while the second is controlled both by this 
internal signalling and by endocrine signals from 
outside the ovary.13 
 
The follicle begins as an oocyte surrounded by a single 
layer of GCs enclosed in turn, by a basement 
membrane. During development, the proliferating GCs 
provide nutrients and various molecular signals to the 
oocyte, which increases in size. Re-organization of the 
follicle and the differentiation and proliferation of the 
GCs results in the formation of an antrum prior to 
ovulation. In these ways, the follicles supports the 
oocyte, both chemically and physically. During this 
development process the follicle migrates from the 
cortex to the medulla and then back again as ovulation 
approaches.13 Cisplatin or cis-diamminedichloro plati-
num is an inorganic compound that is widely prescribed 
for a variety of tumours (germ-cell tumours, advanced 
bladder carcinoma, adrenal cortex carcinoma, breast 
cancer, head and neck carcinoma, lung carcinoma).14 
 
The rat weigh of the control and cisplatin groups were 
performed homogenity test by Levene’s test, and we 
found that there was no significant differrence between 
the control and cisplatin group before and after 
treatment. So, the weigh of the rats were homogenous. 
On the study, before treatment, all rats were performed 
vaginal smear to equal the menstruation cycle. Rats on 
diestrus period were given treatment. The control group 
was injected by NaCl 0.9% IP and the cisplatin group 
were injected by cisplatin 5 mg/kgw IP. At the seventh 
day after treatment, before the rats were slaughtered, 
they were performed vaginal smear. The result of 
vaginal smear on the control rats showed estrus period, 
while on the cisplatin group showed diestrus period. 
The diestrus feature was suitable to the studies of Rivera 
et al and Schauwecker et al, where the ovarian failure 
was determined when the vaginal cytology showed > 15 
days of persistent diestrus.15,16 
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On this study, the expression of KL on cisplatin group 
was lower than the control group. After we performed 
the comparation test by T-paired test, we found the 
significant difference. It supported the following 
studies. In order to visualize and study the direct 
mechanism of chemotherapy-induced ovarian damage 
and primordial follicles injury, healthy human cortical 
ovarian slices were exposed in vitro to therapeutic doses 
of cisplatin. Histology and immunohistochemical stain-
ing showed that chemoterapy induced pregranulosa cell 
swelling, marked pregranulosa cell nuclear swelling and 
primordial follicles architecture disruption with 
disappearance of the lumen and its oocyte. Positive 
apoptotic staining was obtained in the pregranulosa cells 
exposed to chemotherapy but not in controls. Therefore, 
in the human ovary cisplatin acts primarily on the 
pregranulosa cells inducing apoptotic changes, and the 
cells exhibit marked swelling. Familiari et al examined 
ovarian follicles by electron microscopy following 
expossure to chemotherapy. Results have shown that 
follicular cells were enlarged containing cytoplasmic 
elements and the nuclei within the pregranulosa cells 
were also enlarged. Also the primordial follicles 
population was often surrounded by an abnormally thick 
basal lamina.17 
 
In the ovary, c-kit is expressed in oocytes, and KL is 
produced by granulosa cells and is thought to function 
in oocyte growth in a paracrine manner. Expression of 
c-kit is found in oocytes as early as in the primordial 
follicles of newborn mice and the sheep fetus. In the 
mouse, inhibition of the interaction between KL and c-
kit by the specific antibody prevents transition from 
primordial follicles to primary follicles without blocking 
the formation of primordial follicles. Administration of 
anti c-kit antibody (ACK2) to mice has even stopped the 
proliferation of granulosa cells.  
 
Therefore, KL/c-kit interaction appear to be essential for 
the growth initiation of mouse oocytes. In addition, 
Packer et al have shown with in vitro cultures that KL 
(10-100 ng/ml) promotes the growth of oocytes 
collected from 8-days-old mice. Parrot and skinner have 
used rat ovaries and shown that KL (100 ng/ml) induces 
a significant development of primordial follicles. The 
promotional effect of antrum formation by KL (20 or 50 
ng/ml) has also been reported in cultured mouse 
preantral follicles. However, these promotions by KL 
have not been confirmed in other species.18 
 
The study result showed that the amount of primordial, 
primary, secondary, and tertiary follicles on cisplatin 
group were lower than the control group. Comparison 
test result by T-paired test showed that the amount of 
primordial, primary, secondary, and tertiary follicles on 
cisplatin group were different significantly than the 
control group. It supported the following studies. 
 
Chemotherapy has been suggested to induce damage to 
primordial follicles by inducing apoptosis. Electron 
microscopy has shown that within hours of 
chemotherapy exposure, primordial follicles become 
surrounded by abnormally thick basal lamina. A 
substantial body of evidence has documented in vitro 
evidence of primordial follicle apoptosis and 
chemotherapy treatment in vitro has also been shown to 
cause primordial follicle architecture disruption and 
pregranulosa cell swelling. Preliminary in vivo studies 
using human ovarian xenografts in SCID mice have also 
shown indications of primordial follicle apoptosis. More 
research is needed to verify that primordial follicle 
apoptosis does indeed occur in true in vivo conditions, 
and whether the oocyte or surrounding granulosa cells 
are the primary target. Alternatively, other mechanisms 
of damage, such as cortical fibrosis and follicular 
‘‘burn-out’’ have been suggested to explain the variable 
loss of follicular reserves.3 
 
It is clear that chemotherapy results in ovarian cortical 
fibrosis and blood vessel damage. In a study conducted 
on human ovarian tissue exposed to combination 
chemotherapy in vivo, hyalinization of cortical blood 
vessels, neovascularization, and cortical fibrosis were 
observed. These modes of injury result in local 
ischemia, thereby affecting the growth and survival of 
primordial follicles. Triangular areas of fibrosis have 
been observed to coincide with a depletion of primordial 
follicles, indicating that blood vessel damage results in 
primordial follicle injury. This may also impair the 
processes of new vessel formation that are critical for 
normal follicle growth within the territory of the 
damaged vasculature. If apoptosis had initially led to a 
diminished need for blood vasculature, then a uniform 
pattern of primordial follicle loss would be expected; 
this however, is not the observed trend.3 
 
The correlation test between KL expression and amount 
of follicles on the research was not significant, showed 
that there was no association among the amount of KL 
expression and the amounts of primordial, primary, 
secondary, and tertiary follicles on cisplatin group. 
There were some things that we thought as the causes of 
the abscence of the association between KL expression 
and the amount of follicles. The statistic accounting 
which stated that there was no significant association 
between the amount of the expression of kit ligand and 
the amount of the follicles, showed that there was still 
other factors which also played role on folliculogenesis 
process. As we know, that folliculogenesis is the 
process by which the female germ cell develops within 
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the somatic cells of the ovary and matures into a 
fertilizable egg.7 
 
Ovarian follicle is the functional unit of woman’s 
reproduction, consists of oocyte, granulose cell, and 
theca cell. Folliculogenesis involved corporation among 
those three cells and included lots of process such as: 
proliferation of granulose cells, oocyte meiosis, 
steroidogenesis of theca cells, expansion of cummulus. 
So, we need to perform exploration to those factors to 
explain the mechanism of the impairment on the 
folliculogenesis. 
 
 
CONCLUSION 
 
In rat with cisplatin, the expresssion of kit ligand, the 
amount of primordial, primary, secondary, and tertiary 
follicles are low. 
 
 
REFERENCES 
 
1. Sonmezer M and Oktay K. Fertility Preservation in 
Female Patients. Human Reproduction Update. 
2006; Vol.10, No.3 pp: 251-266. 
2. Simon B, Lee SJ, Partridge AH and Runowicz CD. 
Preserving Fertility After Cancer. Cancer J Clin. 
2005; 55: pp211–228. 
3. Meirow D, Biederman H, Anderson RA, dan 
Wallace WHB. Toxicity Of Chemotherapy and 
Radiation on Female Reproduction. Clinical 
Obstetrics and Gynecology. 2010; Vol 53, No 4, 
Pp727–739. 
4. Mead G, Anderson R, Barratt C, Cassoni A, 
Coleman R, Critchley H, Glaser A, Hill E, Mead S, 
Radford J, Randev P, Rule S, Sugden E and Trainer 
P. The Effects of Cancer Treatment on Reproductive 
Functions, Guidance on management. The Royal 
College of Physicians. 2007; p. 1-59. 
5. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici 
J, Schiff E, Raanani H, Levron J and Fridman E. 
Cortical Fibrosis and Blood-Vessels Damage in 
Human Ovaries Exposed to Chemotherapy. Potential 
Mechanisms of Ovarian Injury. Human Reproduct-
ion. 2007; Vol. 22, No.6, pp: 1626–1633. 
6. Rajkovic A, Pangas SA and Matzuk MM. Follicular 
Development: Mouse, sheep and human models. In 
(Neil Jd) Knobil and Neill’s Physiology of 
Reproduction. 2006. 3rd ed. AP. P: 383-424. 
7. Williams CJ, and Erickson GF. Morphology and 
Physiology of the Ovary. 2008. Available From: 
http://www.endotext.org/female/female.1/femalefra
me1.htm./ Download on 5th February 2010. 
8. Celestino JJH, Matos MHT, Saraiva MVA and 
Figueiredo JR. Regulation of Ovarian 
Folliculogenesis by Kit Ligand and The C-Kit 
System in Mammals. Anim. Reprod. 2009; Vol.6, 
No.3, pp: 431-439. 
9. Hutt KJ, McLaughlin EA and Holland MK. Kit 
Ligand and c-Kit Have Diverse Roles During 
Mammalian Oogenesis and Folliculogenesis. 
Molecular Human Reproduction. 2006; Vol.12, No.2 
p. 61–69. 
10. Kalil NGN. Chemotherapy for Advanced Epithelial 
Ovarian Carcinoma. Best Practice & Reasearch 
Clinical Obstetrics and Gynaecology. 2002; Vol.16, 
No.4, pp: 553-571. 
11. Silva JRV, Hurk R. van den, Tol HTA, van, Roelen 
BAJ and Figueiredo JR. The Kit ligand/c- Kit 
Receptor System in Goat Ovaries: Gene Expression 
and Protein Localization. Zygote. 2006; 14, pp: 317–
328. 
12. Carlsson IB. Regulation of Human Ovarian 
Folliculogenesis in Vitro. Thesis for Doctoral 
Degree (PhD). Department of Clinical Science, 
Intervention and Technology, Division of Obstetrics 
and Gynecology, Karolinska University Hospital 
Huddinge/Karolinska Institutet, Stockholm, 
Sweeden. 2008. 
13. Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, 
Zekioglu O, Isik E and Erhan Y. Effect of 
Chemotherapy on Primordial Follicular Reserve of 
Rat: An Animal Model of Premature Ovarian Failure 
and Infertility. Australian and New Zealand Journal 
of Obstetrics and Gynaecology. 2004; 44: p.6–9. 
14. Rivera Z, Hoying JB and Hoyer PB. Residual 
Ovarian Tissue of Follicle-Depleted Mice Expresses 
Genes for Androgen Synthesis and Metabolism of 
Xenobiotic Compounds. Department of Physiology, 
University of Arizona, Tucson AZ, Cardiovascular 
Innovation Institute, Louisville KY. 2007. 
15. Schauwecker PE, Wood RI, and Lorenzana A. 
Neuroprotection Against Excitotoxic Brain Injury in 
Mice After Ovarian Steroid Depletion. Brain Res. 
2009; 1265: p. 37-46. 
16. Meirow D and Nugent D. The Effect of 
Radiotherapy and Chemotherapy on Female. 2001. 
Reproduction. Human Reproduction Update, V. 7, 
No 6: p.535-543. 
17. Senbon S, Hirao Y and Miyano T. 2003. Interactions 
Between The Oocyte and Surrounding Somatic Cells 
in Follicular Development: Lessons from in Vitro 
Culture. Journal of Reproduction and Development, 
Vol 49, No 4, p.259-269. 
18. Knight PG and GlisterC, 2006. TGF-b Superfamily 
Members and Ovarian Follicle Development, 
Review. J Society for Reproduction and Fertility. 
132: p.191–206. 
 
